Q1 26 EPS
$-0.45
BEAT +4.98%
Est. $-0.47
Q1 26 Revenue
$301.7M
BEAT +8.10%
Est. $279.1M
vs S&P Since Q1 26
+69.2%
BEATING MARKET
GH +73.9% vs S&P +4.7%
Market Reaction
Did GH Beat Earnings? Q1 2026 Results
Guardant Health posted a decisive beat across both top and bottom lines in Q1 2026, reporting revenue of $301.67 million, up 48.3% year over year and ahead of the $279.06 million consensus, while its non-GAAP loss of $0.45 per share came in better th… Read more Guardant Health posted a decisive beat across both top and bottom lines in Q1 2026, reporting revenue of $301.67 million, up 48.3% year over year and ahead of the $279.06 million consensus, while its non-GAAP loss of $0.45 per share came in better than the $0.47 estimate by nearly 5%. The standout driver was the company's Shield colorectal cancer screening test, where volumes surged to roughly 44,000 from approximately 9,000 a year ago, lifting Screening segment revenue by over 600% to $41.59 million and underscoring the commercial momentum building around the liquid biopsy franchise. Oncology, the larger segment, contributed $204.95 million on approximately 86,000 tests, with volumes up 47% year over year. Gross margin expanded to 65% GAAP from 63%, though heavy commercial investment pushed sales and marketing costs up 62% to $169.13 million. On the strength of the quarter, Guardant raised its full-year 2026 revenue outlook to $1.30 billion to $1.32 billion, reflecting 32% to 34% growth, and lifted Shield volume targets to 230,000 to 245,000 tests.
Key Takeaways
- • Oncology test volume grew 47% year over year to approximately 86,000 tests
- • Shield screening test volume grew to approximately 44,000 tests from approximately 9,000 in the prior year
- • Increased reimbursement rates for oncology and Shield screening tests
- • Strong receptivity to therapy response monitoring with Guardant Reveal
- • Non-GAAP gross margin improved to 66% from 65%
GH YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
GH Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our first-quarter revenue increased 48% year over year, reflecting strong momentum across the Guardant portfolio. Oncology testing volumes continued to accelerate, reaching 86,000 in the quarter, up 47% year over year. Guardant360 Liquid and Guardant360 Tissue demonstrated significant growth, and we saw strong receptivity to our expansion into therapy response monitoring with Guardant Reveal. We believe these trends, driven by our Smart platform and InfinityAI offerings, position us well for sustained growth and for extending our leadership in precision oncology.”
— Helmy Eltoukhy, Q1 2026 Earnings Press Release
GH Earnings Trends
GH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GH EPS Trend
Earnings per share: estimate vs actual
GH Revenue Trend
Quarterly revenue: estimate vs actual
GH Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 MISS | $-0.39 | $-0.42 | -7.80% | $335.0M | +6.53% |
| Q1 26 BEAT | $-0.47 | $-0.45 | +4.98% | $301.7M | +8.10% |
| Q4 25 MISS FY | $-0.47 | $-0.50 | -6.52% | $281.3M | +3.30% |
| FY Full Year | — | $-1.82 | — | $982.0M | — |
| Q3 25 BEAT | $-0.49 | $-0.39 | +20.33% | $265.2M | +11.87% |
| Q2 25 BEAT | $-0.51 | $-0.44 | +14.53% | $232.1M | +9.85% |